Search research articles
Contact Us
Filters
Showing results (421-430 of 504) with videos related to
Page
of 51
Sort By:
Haematologica
|
February 20, 2025
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
JCI Insight
|
July 7, 2017
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth
V Lokesh Battula, Phuong M Le, Jeffrey C Sun, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
Plos One
|
November 12, 2015
Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis
Samuel A Shelburne, Nadim J Ajami, Marcus C Chibucos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
Marina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Blood
|
August 3, 2007
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha
Steffen Koschmieder, Francesco D'Alò, Hanna Radomska, et al.
Leukemia
|
July 6, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II
Hannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
Page
of 51
Search research articles
Search
Showing results (421-430 of 504) with videos related to
Sort By:
Page
of 51
Haematologica
|
February 20, 2025
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
JCI Insight
|
July 7, 2017
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth
V Lokesh Battula, Phuong M Le, Jeffrey C Sun, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
Plos One
|
November 12, 2015
Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis
Samuel A Shelburne, Nadim J Ajami, Marcus C Chibucos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
Marina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Blood
|
August 3, 2007
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha
Steffen Koschmieder, Francesco D'Alò, Hanna Radomska, et al.
Leukemia
|
July 6, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II
Hannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
Page
of 51